Cardiovascular (CV) Benefit of Empagliflozin Across the Spectrum of CV Risk Factor Control in the EMPA-REG OUTCOME Trial.

Like Comment
Control of multiple cardiovascular (CV) risk factors reduces CV events in individuals with type 2 diabetes (T2D).To investigate this association in a contemporary clinical trial population, including how CV risk factor control affects the CV benefits of empagliflozin, a sodium-glucose co-transporter-2 inhibitor.Post hoc analysis.Randomized CV outcomes trial (EMPA-REG OUTCOME).Empagliflozin or placebo.Risk of CV outcomes - including treatment effect of empagliflozin - by achievement of seven goals for CV risk factor control at baseline: glycated hemoglobin <7.5%, low-density lipoprotein cholesterol <100 mg/dL or statin use, systolic blood pressure <140 mmHg and diastolic blood pressure <90 mmHg, pharmacological renin-angiotensin-aldosterone system blockade, normoalbuminuria, aspirin use, non-smoking.In the placebo group, the hazard ratio (HR) for CV death was 4.00 (95% CI 2.26-7.11) and 2.48 (1.52-4.06) for patients achieving only 0-3 or 4-5 risk factor goals at baseline, respectively, compared to those achieving 6-7 goals. Participants achieving 0-3 or 4-5 goals also had increased risk for the composite outcome of hospitalization for heart failure or CV death (excluding fatal stroke) (HR 2.89 [1.82-4.57] and 1.90 [1.31-2.78], respectively) and 3-point major adverse CV events (HR 2.21 [1.53-3.19] and 1.42 [1.06-1.89]). Empagliflozin significantly reduced these outcomes across all risk factor control categories (P>0.05 for treatment-by-subgroup interactions).CV risk in EMPA-REG OUTCOME was inversely associated with baseline CV risk factor control. Empagliflozin's cardioprotective effect was consistent regardless of multiple baseline risk factor control.


Click here to read the full article @ The Journal of clinical endocrinology and metabolism
Go to the profile of ClinOwl

ClinOwl

The wider, wiser view for healthcare professionals. ClinOwl signposts the latest clinical content from over 100 leading medical journals.
1805 Contributions
1 Followers
0 Following

No comments yet.